This study investigates NICE's evaluation of existing CDF treatments and its potential impact on fun...
Read moreFrom July 2016 NICE will gain decision power by saying yes, no or maybe to cancer drugs entering the...
Read morePharmaceutical companies are able to charge significantly higher prices as these products are addres...
Read moreNew legislation has enabled AIFA to approve reimbursement for Avastin for off-label usage in the tre...
Read moreUpdates on the latest news on NICE's Value Based Assessment, as well as the approval of ultra-orphan...
Read moreIf spending on Hepatitis C drugs exceeds a certain amount, drug manufacturers will be taxed
Read more